Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Annexon (NASDAQ: ANNX) has granted stock options to two new non-executive employees as part of its 2022 Employment Inducement Award Plan. The equity awards, approved on May 14, 2025, include options to purchase 214,000 shares of Annexon common stock at an exercise price of $1.81 per share, matching the closing price on May 15, 2025. The options have a ten-year term and vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.

News Market Reaction

+3.98%

1 alert

+3.98% News Effect

On the day this news was published, ANNX gained 3.98%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 14, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 214,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $1.81, which was the closing price of Annexon’s common stock on May 15, 2025, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

What stock options did Annexon (ANNX) grant to new employees in May 2025?

Annexon granted options to purchase 214,000 shares of common stock at $1.81 per share to two non-executive employees, with a ten-year term and 4-year vesting schedule.

What is the vesting schedule for Annexon's May 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, subject to continued employment.

What was the exercise price for Annexon's May 2025 employee stock options?

The exercise price was $1.81 per share, equal to Annexon's closing stock price on May 15, 2025.

Under which plan were Annexon's May 2025 employee stock options granted?

The options were granted under Annexon's 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).